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Contraceptive management is critical in women with epilepsy because of the potential for 
maternal and fetal risks if unexpected pregnancy develops while on AED treatment. Although 
oral contraceptives (OCs) are widely used by many women with epilepsy, there has been little 
investigation into how interactions among circulating hormones and antiepileptic drugs (AEDs) 
impact both epileptic seizures and contraception. Ethinyl estradiol (EE) is the primary 
component of combined OC pills which are used by several million women worldwide.  The 
present study was undertaken to investigate the potential adverse effect of EE on epileptogenesis 
and seizure activity using the hippocampus kindling model in female mice. Animals were 
stimulated daily without or with EE, given daily for 14 days, at 125% afterdischarge (AD) 
threshold until a fully-kindled state where stage 5 seizures could be elicited consistently. EE 
impacted the development of kindling by acceleration of rate of epileptogenesis. Fully-kindled 
mice were treated with various doses of EE and seizure susceptibility was assessed by seizure 
stage, seizure severity, AD duration, and AD threshold. In acute studies, the AD current 
threshold was dose-dependently reduced by EE treatment. The highest dose tested caused a 
~50% decrease in AD threshold and increased the incidence and severity of seizures in kindled 
mice. In chronic studies, EE treatment caused greater susceptibility to kindling seizures.  These 
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results provide strong evidence that EE exacerbates seizures, lowers seizure threshold, and 
promotes epileptogenic responses, which are consistent with its proconvulsant effects. Such 
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CHAPTER I  
INTRODUCTION 
 
Epilepsy is one of the most common neurological disorders and is characterized by the 
unpredictable reoccurrence of seizures. Epilepsy incidence is gender-dependent with predisposed 
effect to sex-specific hormonal regulation. In approximately 39-60% of women with epilepsy 
(WWE), the condition of catamenial epilepsy occurs in which seizure periodicity is not 
completely random. Instead, seizure events tend to cluster around specific points in the menstrual 
cycle (Reddy, 2010). An increase in seizure activity in WWE occurs at times of high estrogen 
levels such as ovulation and when progesterone levels fall such as the start of menstruation. The 
cyclical changes of estrogen, progesterone, and neurosteroids are now widely believed to be 
important in the pathogenesis of catamenial epilepsy (Reddy, 2013). Although it is known that 
reproductive hormones have properties that alter sensitivity to anticonvulsant drugs and seizures, 
there has been little investigation into how interactions among circulating hormones and 
antiepileptic drugs (AEDs) impact both epileptic seizures and contraception.  
 
Catamenial epilepsy is a multifaceted condition with numerous causes and underlying 
neuroendocrine mechanisms. The most common form of catamenial epilepsy is perimenstrual, in 
which cyclical seizure exacerbations occur around menstruation. Evidence from animal models 
suggests that this enhanced seizure susceptibility during menstrual periods is caused by the 
withdrawal paradigm of progesterone-derived neurosteroids. During menstruation, low serum 
levels of progesterone are present in the body (Reddy 2009). These observations in animal 
models are supported by clinical studies in women, who report seizure exacerbation after 
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neurosteroid synthesis is inhibited by finasteride (Herzog 2003). Neurosteroids are hormones that 
play a crucial role in regulating seizure susceptibility by rapidly altering neuronal excitability 
through GABA-A receptors. Endogenous neurosteroids such as allopregnanolone (AP) modulate 
seizure susceptibility and confer seizure protection in catamenial epilepsy. Due to the fluctuating 
level of hormones in women, current drug therapy for WWE may be significantly compromised.  
 
Contraceptive management in WWE is critical owing to the potential maternal, fetal, and 
neurological risks if contraception or seizure management fails. A wide range of contraceptive 
methods are available for women. These can be grouped in two distinct categories: hormonal and 
non-hormonal. Hormonal methods of contraception widely used by women of child-bearing age 
include injectable progestogens, combined OC pills, and contraceptive patches. These methods, 
unlike barrier methods, are highly dependent on correct use and individual lifestyles. OCs are the 
most common hormonal contraceptives and are designed to stimulate the 28-day natural 
menstrual cycle. Combined OC pills are composed of low-dose synthetic estrogen and 
progestogen and are usually taken for 21 days with a 7 day gap.  
 
Ethinyl estradiol (EE) is the major estrogen used in OCs in the form of synthetic EE or 
mestranol, a prodrug which is converted to EE in the body. Currently available combined OCs 
can be divided into three types: monophasic (only one dose of estrogen and progestogen during 
the 21 days), biphasic (varying doses of estrogen and progestogen) and triphasic (varying doses 
of estrogen and progestogen). Amounts of estrogen and progesterone are fixed in monophasic 
combinations and as a result, blood levels rise and fall together. In biphasic and triphasic 
combinations, altering doses of progesterone and estrogen are delivered to mimic physiological 
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levels as seen during the cycle. Non-hormonal contraceptive methods include intrauterine 
devices (IUDs), barrier methods such as condoms, and others. The non-hormonal methods have 
been regarded as highly effective and may be ideal for women with epilepsy since the 
contraceptive mechanisms of these methods are undeterred by hepatic enzymes and drug-
interactions (Reddy, 2010).  
 
It is essential to understand the impact of reproductive hormones on seizures and the 
pharmacological effect of OCs for effective contraception and seizure management in WWE. 
There is no strong evidence that the use of OCs increase the risk of seizures in many WWE. 
Although some reports suggest that OCs might exacerbate seizures, most studies show no effect 
of estrogen-based contraceptives on seizure frequency. However, there are many factors to 
consider in the choice of AED therapy and hormonal contraception, since some AEDs can 
reduce the efficacy of OCs owing to pharmacokinetic interactions. OCs are widely used because 
of their high effectiveness in stimulating the natural menstrual cycle but many AEDs can 
influence the effectiveness of hormonal contraception and pose a serious risk. These interactions 
between AEDs and OCs can influence drug efficacy, pregnancy prevention, and seizure 
exacerbation.  
 
Progesterone is a powerful anticonvulsant hormone and reduces seizure frequency due to its 
metabolic conversion to allopregnanolone (AP) in the brain (Reddy, 2004). AP is an endogenous 
neurosteroid that exhibits neuroprotective affects through the positive modulation of GABAA 
receptors (Reddy, 2004). This supports emerging evidence that neurosteroids derived from 




In contrast, estrogens are generally found to have proconvulsant properties which cause 
periovulatory seizure exacerbation attributed to a surge of estrogen mid-cycle. The antagonistic 
role of estrogen to progesterone, in conjunction with the fluctuation of other reproductive 
hormone levels during the menstrual cycle, can substantially increase the onset of seizures. As a 
result, WWE have a much greater disposition to the risk of endocrine dysfunction, reduced 
reproduction, and altered function of the hypothalamic-pituitary axis due to the impact of 
seizures. Furthermore, WWE have much higher possibility of developing polycystic ovaries and 
approximately 30% of WWE experience irregular menstrual cycles (Crawford, 2005). 
A rise in WWE showing inadequate seizure control with AED treatment can be attributed to 
changes in the circulating levels of estrogen and progesterone during the menstrual cycle (Reddy, 
2010). AEDs are mainly metabolized by the Cytochrome P450 3A4 (CYP3A4) system 
(Crawford, 2002). As a result of CYP3A4 induction by AEDs, there is a sharp increase in the 
metabolism of the estrogen and progesterone components of OCs and their circulating serum 
levels are reduced by 50% (Crawford, 1990). Moreover, some OCs can increase the metabolism 
of AEDs by increased induction of hepatic enzymes which can have serious consequences and 
contribute to elevated seizure incidence. This antagonistic effect of AEDs and OCs lead to both a 
reduced efficacy of hormonal contraceptives and an increase in seizure susceptibility.  
 
Despite wide-spread use of OCs, their impact on seizures has been less well studied. The 
pharmacokinetic interactions affecting enzyme-inducing AEDs and OCs pose a serious risk and 
studies indicate that OC failures are the cause of one in four unplanned pregnancies in WWE 
(Fairgrieve, 2000; Coulam, 1979). Patient-awareness programs on AED interactions with OCs 
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may also help to improve contraception efficacy in WWE (Reddy, 2010). EE has been shown to 
increase neuronal excitability through proconvulsant effects in clinical and animal seizure 
models (Backstrom, 1984; Saberi, 2003). EE (17α-ethinyl estradiol) is classified as one of the 
major orally bioactive estrogens and is the major component of combined OC pills. Forms of 
combined OCs which contain EE are used by several million women worldwide. The role of EE 
in the pathophysiology of epilepsy is unclear and there is a lack of clinically relevant studies that 
explore the effect of EE on seizure susceptibility. Further investigation may help reveal some of 
the effects of OCs, including their role on seizures in WWE. Therefore, this study was 
undertaken to investigate the potential adverse effect of EE on epileptogenesis and seizure 







Adult female C57BL/6 mice, with masses of 25 to 30g each were used in this study. All mice 
were housed four to a cage with access to food and water ad libitum. The mice were housed in an 
environmentally controlled animal facility with a 12 h light/dark cycle. The animals were cared 
for in strict compliance with the guidelines outlined in the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals. All animal procedures were performed in a protocol 
approved by the university’s Institutional Animal Care and Use Committee. 
 
Hippocampus Kindling Model of Epilepsy 
To study seizure modulating activity of EE, we used the hippocampus kindling model, which is 
the best model of human temporal lobe epilepsy characterized by progressive complex partial 
seizures with secondary generalization (Albright and Burnham, 1980). A mild focal, 
nonconvulsant electrical stimulus to the hippocampus on a daily basis leads to the development 
of a kindled state exhibiting electrographic and behavioral seizures. In mouse kindling, the focal 
electroencephalogram afterdischarge (AD) models complex partial seizures, whereas the 
behavioral motor seizure stages 4/5 models generalized seizures. The ADs are first localized to 
the region of stimulation but propagate to other parts of the brain with repeated stimulation. As 
the stimulations generalize to other regions of the brain, the animal becomes epileptic leading to 





Electrode implantation and stimulation procedures for mouse hippocampus kindling were 
performed as described previously (Reddy et al., 2012). Mice were anesthetized by an 
intraperitoneal injection of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). A 
twisted bipolar stainless-steel wire electrode (model MS303/1; Plastic Products, Roanoke, VA) 
was stereotaxically implanted in the right hippocampus (2.9 mm posterior and 3.0 mm lateral to 
bregma and 3.0 mm below the dorsal surface of the skull) using the Franklin and Paxinos atlas 
and anchored with dental acrylic to four jeweler’s screws placed in the skull. A period of 7 to 10 
days was allowed for recovery.  
 
AD Threshold (ADT) Determination and Kindling Stimulation  
The stimulation paradigm consisted of 1-ms duration, bipolar, square current pulses delivered at 
60 Hz for 1s using a kindling stimulator (A-M Systems, Sequim, WA). The ADT was 
determined by stimulating at 5-min intervals beginning with an intensity of 25 µA and increasing 
in steps of 25 µA until an AD of at least 5s was obtained. Stimulation on consecutive days used a 
stimulation intensity of 125% threshold value. Seizure activity after each stimulation was rated 
according to the criterion of Racine (1972) as modified for the mouse: stage 0, no response or 
behavior arrest; stage 1, chewing or head nodding; stage 2, chewing and head nodding; stage 3, 
forelimb clonus; stage 4, bilateral forelimb clonus and rearing; and stage 5, falling. The AD was 
recorded from the hippocampus electrode with a Grass CP511 preamplifier (Astro-Med, West 
Warwick, RI) and stored in digital form using Axoscope 8.1 (Axon Instruments, Foster City, 
CA). AD duration was the total duration of hippocampal electrographic spike activity (amplitude 
>2x baseline) occurring in a rhythmic pattern at a frequency of 1 Hz. The day of ADT 
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determination was considered day 0 of kindling. Stimulation was continued on a 5 days/week 
schedule each afternoon. Kindling stimulation was delivered daily until stage 5 seizures were 
elicited on 3 consecutive days. Mice were used for drug testing when they consistently exhibited 
stage 5 seizures after stimulation, which is considered the “fully kindled” state. 
 
Test Drugs and Treatment Protocols 
Stock solutions of EE (Sigma-Aldrich, St. Louis, MO) for injections were made in sorbital-based 
solubilizer in saline, and additional dilutions were made using sterile saline. Drug solutions were 
administered in a volume equaling 1% of the animal’s body weight.  To examine the ability of 
EE to modulate the expression of seizures in the acute study, fully kindled mice were injected 
subcutaneously (SC) with EE (10-100 mg/kg) fifteen minutes prior to stimulation. After each 
stimulation, the behavior seizure expression, electrographic AD activity and ADT were recorded. 
 
Data Analysis 
Group data are expressed as the mean ± standard error of the mean (SEM). To construct dose-
response curves, EE was tested at several doses spanning the dose producing 10% change and 
more towards the ED50 dose. Differences in kindling seizure stage between groups were 
compared with appropriate nonparametric test for significance. Comparison of means of the AD 
duration between groups was made with one-way analysis of variance, followed by unpaired 
two-tailed Student’s t-test. Comparison of the mean ADT for seizures stage and seizure duration 
in fully kindled animals was made by unpaired Student’s t-test. In all statistical tests, the 






Acute Effects of EE on Hippocampus Kindling Seizure Activity  
To investigate whether EE displays proconvulsant-like activity, we explored its acute effects on 
ADT, seizure expression, and electroencephalogram (EEG) AD activity fifteen minutes after SC 
injection in kindling model of epilepsy (Fig.1). Mice were kindled daily until they reach stage 5 
seizures (Fig.2). Fully kindled female mice were treated with increasing doses of EE and the 
acute effects on ADT are displayed in Figure 3. The results show that the ADTs were reduced 
significantly 0.25-hour post-EE treatment in a dose dependent manner. The lowest dose tested 
(10 mg/kg) failed to produce any significant changes in ADT. However, treatment with 50 mg/kg 
EE caused a 25% decrease in ADT. The highest dose tested (100 mg/kg) caused an approximate 
50% decrease in ADT. The significant decrease in ADTs required to elicit stage 5 seizure (SS5) 
response confirms that EE is an excitatory steroid that can elicit pro-convulsive effects in 
epileptic animals. Parameters of electrographic AD activity were compared by measuring AD 
duration (ADD) at 50% ADT. As indicated by EEG AD activity, seizure incidence is markedly 
higher in mice treated with increasing doses of EE (Fig.4).  This significant difference in EEG 
AD activity between vehicle and treatment groups indicates that EE enhances neuronal 
excitability in female mice.  
 
Chronic Effects of EE on Hippocampus Kindling Seizure Activity 
To simulate the daily use of OCs by women, we tested chronic sub-effective doses of EE on 
seizure activity in mice that were treated daily with EE (25 mg/kg, sc) for 21 days.  Then, we 
13 
 
assessed treatment impact on ADT, seizure expression, and AD activity on the 22nd day.  
Subsequently, we also tested the effect of EE on seizure parameters fifteen minutes after SC 
injection. The seizure activity data in fully-kindled female mice were treated daily with EE for 3 
weeks is displayed in Figure 5. Mice displayed a reduced ADTs after the chronic treatment as 
compared to controls not exposed to any drug (Fig.5).  In dose-response studies in chronic 
studies, mice displayed ADTs that were reduced significantly 0.25-hour post-EE treatment in a 
dose dependent manner (Fig.5). The low dose EE (10 mg/kg) failed to produce any significant 
changes in ADT. However, treatment with 25 mg/kg EE caused a significant decrease in ADT. 
The AD duration was increased to a greater extend in EE group compared to control.  There was 
a significant decrease in ADTs required to elicit stage 4/5 seizure in EE-treated mice, which 







The results indicate that treatment with EE was associated with significant effects on seizure 
activity in epileptic female mice. Our results in the hippocampus kindling model provide strong 
evidence that EE affects seizure expression, seizure threshold and AD duration in fully kindled 
mice. These effects are evident from the ADTs required to elicit SS5 being significantly lowered 
post-EE treatment in a dose-dependent manner. Such proconvulsant-like facilitating effect was 
noted in both acute and chronic settings. This evidence suggests that brain regions close to the 
site of stimulation were sensitive to the pro-convulsive effects of EE. The lowered ADTs in the 
hippocampus kindling model are consistent with observations in previous studies showing that 
high EE levels are comparable to that observed in females at the proestrus stage of the estrous 
cycle (Edwards, 1999). The results demonstrate that EE increases neuronal excitability and 
facilitates seizure susceptibility via reduction of ADTs in the hippocampus kindling model.  
 
It has been reported in WWE that a positive correlation exists between seizure susceptibility and 
the estrogen-to-progesterone ratio. This positive correlation is consistent with serum hormone 
levels during perimenstrual and periovulatory periods and reported seizure exacerbation in 
catamenial epilepsy. Therefore, the increase in the ratio of estrogen-to-progesterone levels during 
these periods may partly contribute to seizure exacerbation and may facilitate some forms of 




There are many underlying mechanisms influenced by EE, whereby it is difficult to predict its 
net effect in the brain. Rats chronically exposed to EE have shown increased number and density 
of dendritic spines and excitatory synapses on hippocampal neurons. This mechanism increases 
the synchronization of synaptically driven neuronal firing in the hippocampus and could be 
relevant to EE’s proconvulsant effects in animal models. EE may also increase excitability 
through modulation of neuropeptides and increased levels of brain-derived neurotrophic factor 
(BDNF) in the hippocampus, shown to have both protective actions and increase hippocampus 
excitability (Scharfman and MacLusky, 2006). EE and BDNF have many effects that could 
influence seizures and epilepsy because they both influence neuropeptide Y (Veliskova, 2007).  
 
The dose and time dependent properties of EE are well reported. The rapid onset of EE may be 
due to its direct interactions at the membrane level or through a post-membrane secondary 
messenger cascade (Saberi, 2001). Receptors for estrogens include various membrane-associated 
and cell nuclear receptors. The cell nuclear receptors can also localize to the plasma membrane 
and activate numerous signaling pathways (Reddy, 2014). The G-protein coupled membrane 
estrogen receptors may also be activated by EE, producing actions on many downstream signal 
transduction cascades (Scharfman and MacLusky, 2006). In addition to traditional receptor-
mediated effects, EE affects neuronal excitability due to its organizational effects on synaptic 
structure and function. Through this mechanism, EE enhances glutamate receptor-mediated 
excitatory neurotransmission (Smith, 1988; Wong and Moss, 1994) and decreases GABAergic 
inhibition (Murphy, 1998). The direct effects on glutamate receptors and indirect effects through 
an increase in dendritic spine density of hippocampal NMDA receptor have been shown to be 
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involved in EE modulation of the NMDA receptor function (Rudick and Woolley, 2001; 
Woolley and McEwen, 1994; Woolley, 1997).  
 
In conclusion, these studies confirm that EE is proconvulsant steroid that can elicit exacerbation 
of seizure activity in epileptic animals. The central effects of EE in the hippocampus kindling 
model provide evidence that EE may show similar pro-epileptic effects upon long-term 
administration, such as that present in oral contraceptive pills. Furthermore, our results are 
consistent with clinical reports of increased generalized seizure incidence during peak estrogen 
levels (Backstrom, 1984). It is likely that such effects may manifest an increase in seizure risk in 
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Figure 1. A mouse with an implanted bipolar kindling electrode in the hippocampus. 
 
Figure 2. Progression of hippocampus kindling development in mice. 
Panel A shows progression of behavioral seizure stage following each stimulation. Panel B 
shows progression of AD duration following each stimulation. Data was presented as mean ± 






Figure 3. Dose-dependent effect of EE on seizure activity in fully-kindled mice. 
Panel A shows intensity of ADT current for eliciting generalized (stage 4/5) behavioral seizures 
after EE treatment. Panel B shows duration of behavior (stage 4/5) seizures after EE treatment. 
Panel C shows the duration of AD after EE treatment. Panel D shows the dose-response of 
percent animals exhibiting generalized seizures.  
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Control (No EE) 
 
EE treatment (100 mg/kg sc)  
 
 
Figure 4. Sample traces of AD duration in control and EE-treated mice.  
Representative traces illustrate EE exacerbation of electrographic seizure activity in a fully 
kindled mouse. Traces show depth recording from a right hippocampus bipolar (stimulating and 
recording) electrode. Arrows indicate onset of the 1-s kindling stimulus, which is followed by the 














Figure 5. Dose-dependent effect of EE on seizure activity in mice treated chronically with 
EE (25 mg/kg, sc) for 21 days.  
Panel A shows intensity of ADT current for eliciting generalized (stage 4/5) behavioral seizures 
after EE treatment. Panel B shows duration of behavior (stage 4/5) seizures after EE treatment. 
Panel C shows the duration of AD after EE treatment. Panel D shows the dose-response of 
percent animals exhibiting generalized seizures.  
 
